You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrifluoperazine
Accession NumberDB00831  (APRD00173, DB08616)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]
Structure
Thumb
Synonyms
10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
10-[3-(4-METHYL-piperazin-1-yl)-propyl]-2-trifluoromethyl-10H-phenothiazine
Trifluoperazina
Trifluoperazine
Trifluoperazinum
Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
Trifluoroperazine
Trifluperazine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-flurazine Tab 1mgtablet1.18 mgoralNovopharm Limited1971-12-311996-09-10Canada
Novo-flurazine Tab 20mgtablet23.6 mgoralNovopharm Limited1971-12-311996-09-10Canada
Novo-trifluzine - Tab 10mgtablet11.8 mgoralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 2mgtablet2.36 mgoralNovopharm Limited1971-12-312013-06-03Canada
Novo-trifluzine - Tab 5mgtablet5.9 mgoralNovopharm Limited1971-12-312013-06-03Canada
PMS Trifluoperazine HCl Syrup 11.8mg/mlsyrup10 mgoralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 10mgtablet10 mgoralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 1mgtablet1 mgoralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 20mgtablet20 mgoralPharmascience Inc1988-12-311996-09-10Canada
PMS Trifluoperazine Tab 2mgtablet2 mgoralPharmascience Inc1988-12-312012-03-14Canada
PMS Trifluoperazine Tab 5mgtablet5 mgoralPharmascience Inc1988-12-312012-03-14Canada
PMS-trifluoperazine HCl Syr 1.18mg/mlsyrup1 mgoralPharmascience Inc1988-12-312012-10-17Canada
Stelazine Tab 10mgtablet10 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 1mgtablet1 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-11-30Canada
Stelazine Tab 2mgtablet2 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-312000-10-18Canada
Stelazine Tab 5mgtablet5 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1993-12-312000-09-28Canada
Terfluzine Concentratesyrup10 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312011-08-03Canada
Terfluzine-1tablet1 mgoralValeant Canada Lp Valeant Canada S.E.C.1974-12-312011-08-03Canada
Terfluzine-10tablet10 mgoralValeant Canada Lp Valeant Canada S.E.C.1973-12-312011-08-03Canada
Terfluzine-2tablet2 mgoralValeant Canada Lp Valeant Canada S.E.C.1978-12-312011-08-03Canada
Terfluzine-5tablet5 mgoralValeant Canada Lp Valeant Canada S.E.C.1968-12-312011-08-03Canada
Trifluoperazinetablet5 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Trifluoperazinetablet20 mgoralAa Pharma Inc1984-12-31Not applicableCanada
Trifluoperazinetablet2 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Trifluoperazinetablet10 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Trifluoperazinetablet1 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Trifluoperazine 10mg Tabletstablet10 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 1mg Tabletstablet1 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 2mg Tabletstablet2 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine 5mg Tabletstablet5 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Trifluoperazine Tab 10mgtablet10 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 10mgtablet10 mgoralPro Doc Limitee1977-12-312010-07-13Canada
Trifluoperazine Tab 1mgtablet1 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 1mgtablet1 mgoralPro Doc Limitee1976-12-312010-07-13Canada
Trifluoperazine Tab 2mgtablet2 mgoralPro Doc Limitee1976-12-312010-07-13Canada
Trifluoperazine Tab 2mgtablet2 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 5mgtablet5 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Trifluoperazine Tab 5mgtablet5 mgoralPro Doc Limitee1976-12-312010-07-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trifluoperazinetablet, film coated2 mg/1oralSTAT Rx USA LLC1981-11-20Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated1 mg/1oralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated10 mg/1oralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated1 mg/1oralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated5 mg/1oralREMEDYREPACK INC.2012-09-27Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated1 mg/1oralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated2 mg/1oralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated2 mg/1oralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated2 mg/1oralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated2 mg/1oralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated5 mg/1oralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated1 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-08-22Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated5 mg/1oralSandoz Inc1981-11-20Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated5 mg/1oralUpsher Smith Laboratories, Inc.2015-03-09Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1997-08-29Not applicableUs
Trifluoperazine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1998-03-04Not applicableUs
Trifluoperazine Hydrochloridetablet1 mg/1oralREMEDYREPACK INC.2011-12-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EskazineNot Available
EskazinylNot Available
JatroneuralNot Available
ModalinaNot Available
StelazineNot Available
TerfluzineNot Available
TrifluoperazNot Available
TriftazinNot Available
Brand mixtures
NameLabellerIngredients
Stelabid ForteGlaxosmithkline Inc
Stelabid No 1Glaxosmithkline Inc
Stelabid No 2Glaxosmithkline Inc
Salts
Name/CASStructureProperties
Trifluoperazine Hydrochloride
440-17-5
Thumb
  • InChI Key: BXDAOUXDMHXPDI-UHFFFAOYSA-N
  • Monoisotopic Mass: 479.117658566
  • Average Mass: 480.417
DBSALT000569
Categories
UNII214IZI85K3
CAS number117-89-5
WeightAverage: 407.496
Monoisotopic: 407.164303088
Chemical FormulaC21H24F3N3S
InChI KeyInChIKey=ZEWQUBUPAILYHI-UHFFFAOYSA-N
InChI
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
PharmacodynamicsTrifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionTrifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life10-20 hours
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9946
Blood Brain Barrier+0.9814
Caco-2 permeable+0.6856
P-glycoprotein substrateSubstrate0.8529
P-glycoprotein inhibitor IInhibitor0.9058
P-glycoprotein inhibitor IIInhibitor0.9089
Renal organic cation transporterInhibitor0.6842
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9109
CYP450 3A4 substrateNon-substrate0.594
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.5618
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8247
Ames testNon AMES toxic0.8944
CarcinogenicityNon-carcinogens0.9446
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8411 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9327
hERG inhibition (predictor II)Inhibitor0.8556
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Sandoz inc
  • Wockhardt eu operations (swiss) ag
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral1.18 mg
Tabletoral23.6 mg
Tabletoral11.8 mg
Tabletoral2.36 mg
Tabletoral5.9 mg
Syruporal1 mg
Tabletoral
Syruporal10 mg
Tabletoral1 mg
Tabletoral10 mg
Tabletoral2 mg
Tabletoral20 mg
Tabletoral5 mg
Tabletoral1 mg/1
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral5 mg/1
Prices
Unit descriptionCostUnit
Trifluoperazine HCl 10 mg tablet1.7USD tablet
Trifluoperazine 10 mg tablet1.63USD tablet
Trifluoperazine HCl 5 mg tablet1.09USD tablet
Trifluoperazine 5 mg tablet1.08USD tablet
Trifluoperazine HCl 2 mg tablet0.89USD tablet
Trifluoperazine 2 mg tablet0.86USD tablet
Trifluoperazine HCl 1 mg tablet0.59USD tablet
Trifluoperazine 1 mg tablet0.58USD tablet
Apo-Trifluoperazine 20 mg Tablet0.58USD tablet
Apo-Trifluoperazine 10 mg Tablet0.29USD tablet
Apo-Trifluoperazine 5 mg Tablet0.24USD tablet
Apo-Trifluoperazine 2 mg Tablet0.18USD tablet
Apo-Trifluoperazine 1 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility12.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.03HANSCH,C ET AL. (1995)
logS-4.52ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00876 mg/mLALOGPS
logP4.87ALOGPS
logP4.66ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity110.98 m3·mol-1ChemAxon
Polarizability41.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03kc-9740000000-e505b8906d154e2285a4View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AB06
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Trifluoperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Trifluoperazine can be increased when it is combined with Abiraterone.
AcebutololTrifluoperazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Trifluoperazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Trifluoperazine.
adipiplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Trifluoperazine.
AgomelatineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Trifluoperazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alfaxalone.
AlfentanilTrifluoperazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trifluoperazine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Trifluoperazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.
AlphacetylmethadolTrifluoperazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Trifluoperazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trifluoperazine.
AlprenololTrifluoperazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Trifluoperazine.
AmisulprideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trifluoperazine.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Trifluoperazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amperozide.
AmphetamineTrifluoperazine may decrease the stimulatory activities of Amphetamine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Trifluoperazine.
AripiprazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aripiprazole.
ArotinololTrifluoperazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Trifluoperazine.
ArtemetherThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Trifluoperazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Asenapine.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Trifluoperazine.
AtenololTrifluoperazine may increase the hypotensive activities of Atenolol.
AtovaquoneThe serum concentration of Trifluoperazine can be increased when it is combined with Atovaquone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Trifluoperazine.
AzaperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Azaperone.
AzelastineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trifluoperazine.
AzithromycinThe metabolism of Trifluoperazine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.
BefunololTrifluoperazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzocaine.
BenzphetamineTrifluoperazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Trifluoperazine.
BetaxololTrifluoperazine may increase the hypotensive activities of Betaxolol.
BevantololTrifluoperazine may increase the hypotensive activities of Bevantolol.
BezitramideTrifluoperazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololTrifluoperazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Trifluoperazine.
BopindololTrifluoperazine may increase the hypotensive activities of Bopindolol.
BortezomibThe metabolism of Trifluoperazine can be decreased when combined with Bortezomib.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trifluoperazine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trifluoperazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
BrimonidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Trifluoperazine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Trifluoperazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brotizolam.
BufuralolTrifluoperazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trifluoperazine.
BupranololTrifluoperazine may increase the hypotensive activities of Bupranolol.
BuprenorphineTrifluoperazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trifluoperazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine.
ButacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butethal.
ButorphanolTrifluoperazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluoperazine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Trifluoperazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trifluoperazine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Trifluoperazine.
CaffeineThe metabolism of Trifluoperazine can be decreased when combined with Caffeine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Trifluoperazine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Trifluoperazine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Trifluoperazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trifluoperazine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carbinoxamine.
CarfentanilTrifluoperazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Trifluoperazine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Trifluoperazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.
CarteololTrifluoperazine may increase the hypotensive activities of Carteolol.
CarvedilolTrifluoperazine may increase the hypotensive activities of Carvedilol.
CeliprololTrifluoperazine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Trifluoperazine.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Trifluoperazine.
CetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trifluoperazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorphenamine.
ChlorphentermineTrifluoperazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trifluoperazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Trifluoperazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Trifluoperazine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trifluoperazine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Trifluoperazine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Trifluoperazine.
CitalopramThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Trifluoperazine.
ClemastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Trifluoperazine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Trifluoperazine.
clomethiazoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Trifluoperazine.
ClomipramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Trifluoperazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Trifluoperazine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Trifluoperazine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trifluoperazine.
ClotrimazoleThe metabolism of Trifluoperazine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Trifluoperazine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Trifluoperazine.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Trifluoperazine.
CocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cocaine.
CodeineTrifluoperazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trifluoperazine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Trifluoperazine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Trifluoperazine.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Trifluoperazine.
CyclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trifluoperazine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Trifluoperazine.
CyproheptadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Trifluoperazine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Trifluoperazine.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Trifluoperazine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Trifluoperazine.
DantroleneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Trifluoperazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trifluoperazine.
DapoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dapoxetine.
DapsoneThe serum concentration of Trifluoperazine can be increased when it is combined with Dapsone.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Trifluoperazine.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Trifluoperazine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Trifluoperazine.
DeferasiroxThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.
deramciclaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Trifluoperazine.
DesloratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Trifluoperazine.
DetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Trifluoperazine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trifluoperazine.
DextroamphetamineTrifluoperazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trifluoperazine.
DextromoramideTrifluoperazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Trifluoperazine.
DextropropoxypheneTrifluoperazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trifluoperazine.
DezocineTrifluoperazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Trifluoperazine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Trifluoperazine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Trifluoperazine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Trifluoperazine.
DifenoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Trifluoperazine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trifluoperazine.
DihydrocodeineTrifluoperazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trifluoperazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine.
DihydroetorphineTrifluoperazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Trifluoperazine.
DihydromorphineTrifluoperazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Trifluoperazine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Trifluoperazine.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Trifluoperazine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Diphenhydramine.
DiphenoxylateTrifluoperazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Trifluoperazine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Trifluoperazine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Trifluoperazine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Trifluoperazine.
DoramectinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Trifluoperazine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Trifluoperazine.
DoxycyclineThe serum concentration of Trifluoperazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
DoxylamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Doxylamine.
DPDPETrifluoperazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Trifluoperazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Trifluoperazine.
DrotebanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluoperazine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trifluoperazine.
EcgonineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Trifluoperazine.
EfavirenzThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trifluoperazine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Trifluoperazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trifluoperazine.
EntacaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Trifluoperazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Trifluoperazine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Trifluoperazine.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Trifluoperazine.
EscitalopramThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.
EsmololTrifluoperazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Trifluoperazine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Trifluoperazine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Trifluoperazine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trifluoperazine.
EthanolTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trifluoperazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trifluoperazine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Trifluoperazine.
EthosuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl loflazepate.
EthylmorphineTrifluoperazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trifluoperazine.
EtidocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluoperazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Trifluoperazine.
EtorphineTrifluoperazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Trifluoperazine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Trifluoperazine.
EzogabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fenfluramine.
FentanylTrifluoperazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trifluoperazine.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Trifluoperazine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Trifluoperazine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Trifluoperazine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Trifluoperazine.
FlibanserinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine.
FluspirileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Trifluoperazine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Trifluoperazine.
GabapentinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Trifluoperazine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Trifluoperazine.
GlutethimideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Glutethimide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Trifluoperazine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Trifluoperazine.
GuanfacineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Trifluoperazine.
HalofantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Halofantrine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Trifluoperazine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluoperazine.
HalothaneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.
HeroinTrifluoperazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Trifluoperazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.
HydrocodoneTrifluoperazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trifluoperazine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Trifluoperazine.
HydromorphoneTrifluoperazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trifluoperazine.
Hydroxyamphetamine hydrobromideTrifluoperazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Trifluoperazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Trifluoperazine.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Trifluoperazine.
IloperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Trifluoperazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trifluoperazine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Trifluoperazine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Trifluoperazine.
IndalpineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.
IndenololTrifluoperazine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Trifluoperazine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Trifluoperazine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Trifluoperazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trifluoperazine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Trifluoperazine.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Trifluoperazine.
KetamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Trifluoperazine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trifluoperazine.
KetobemidoneTrifluoperazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Trifluoperazine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Trifluoperazine.
LabetalolTrifluoperazine may increase the hypotensive activities of Labetalol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Trifluoperazine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Trifluoperazine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Trifluoperazine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Trifluoperazine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Trifluoperazine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Trifluoperazine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Trifluoperazine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Trifluoperazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Trifluoperazine.
LevobunololTrifluoperazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Trifluoperazine.
Levomethadyl AcetateTrifluoperazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Trifluoperazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levomilnacipran.
LevorphanolTrifluoperazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trifluoperazine.
LidocaineThe metabolism of Trifluoperazine can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Trifluoperazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Trifluoperazine.
LisdexamfetamineTrifluoperazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Trifluoperazine.
LithiumThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lithium.
LofentanilTrifluoperazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Trifluoperazine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Trifluoperazine.
LoratadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trifluoperazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Trifluoperazine.
LosartanThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.
Lu AA21004The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lu AA21004.
LumefantrineThe serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Trifluoperazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trifluoperazine.
MeclizineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Medetomidine.
MefloquineThe serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Melperone.
MephentermineTrifluoperazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.
MequitazineTrifluoperazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.
MethadoneTrifluoperazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.
Methadyl AcetateTrifluoperazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Trifluoperazine.
MethamphetamineTrifluoperazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trifluoperazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Trifluoperazine.
MetipranololTrifluoperazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.
MetoprololTrifluoperazine may increase the hypotensive activities of Metoprolol.
MetyrosineTrifluoperazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Trifluoperazine.
MexiletineThe metabolism of Trifluoperazine can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Trifluoperazine.
MilnacipranThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Trifluoperazine.
MirtazapineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trifluoperazine.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Trifluoperazine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.
MolindoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Molindone.
MorphineTrifluoperazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trifluoperazine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trifluoperazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.
NabiloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nabilone.
NadololTrifluoperazine may increase the hypotensive activities of Nadolol.
NalbuphineTrifluoperazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trifluoperazine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trifluoperazine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Trifluoperazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Trifluoperazine.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Trifluoperazine.
NevirapineThe metabolism of Trifluoperazine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Trifluoperazine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Trifluoperazine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Trifluoperazine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Trifluoperazine.
NitrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Trifluoperazine.
NormethadoneTrifluoperazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Trifluoperazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trifluoperazine.
OlanzapineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Trifluoperazine.
OndansetronThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ondansetron.
OpiumTrifluoperazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Trifluoperazine.
OrphenadrineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Trifluoperazine.
OsanetantThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Trifluoperazine.
OsimertinibThe serum concentration of Trifluoperazine can be decreased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.
OxprenololTrifluoperazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Trifluoperazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxybuprocaine.
OxycodoneTrifluoperazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trifluoperazine.
OxymorphoneTrifluoperazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trifluoperazine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Trifluoperazine.
PaliperidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Trifluoperazine.
ParaldehydeTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Trifluoperazine.
ParoxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.
Peginterferon alfa-2bThe serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.
PenbutololTrifluoperazine may increase the hypotensive activities of Penbutolol.
PentazocineTrifluoperazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trifluoperazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.
PerampanelThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perphenazine.
PethidineTrifluoperazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trifluoperazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trifluoperazine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Trifluoperazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Trifluoperazine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Phenoxyethanol.
PhentermineTrifluoperazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Trifluoperazine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Trifluoperazine.
PimozideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.
PindololTrifluoperazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Trifluoperazine.
PizotifenThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Trifluoperazine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trifluoperazine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Trifluoperazine.
PractololTrifluoperazine may increase the hypotensive activities of Practolol.
PramipexoleTrifluoperazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Trifluoperazine.
PrazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Trifluoperazine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Trifluoperazine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trifluoperazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Trifluoperazine.
PrimaquineThe serum concentration of Trifluoperazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Trifluoperazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluoperazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Trifluoperazine.
ProguanilThe serum concentration of Trifluoperazine can be increased when it is combined with Proguanil.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trifluoperazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Trifluoperazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Trifluoperazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Trifluoperazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Propoxycaine.
PropranololTrifluoperazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trifluoperazine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trifluoperazine.
PSD502The risk or severity of adverse effects can be increased when Trifluoperazine is combined with PSD502.
PyrimethamineThe serum concentration of Trifluoperazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Trifluoperazine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trifluoperazine.
QuinacrineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Trifluoperazine.
QuinidineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Trifluoperazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Trifluoperazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Trifluoperazine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trifluoperazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.
RemifentanilTrifluoperazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trifluoperazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trifluoperazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Trifluoperazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Trifluoperazine.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Trifluoperazine.
RifampicinThe metabolism of Trifluoperazine can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trifluoperazine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Trifluoperazine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trifluoperazine.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Trifluoperazine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Trifluoperazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Trifluoperazine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Trifluoperazine.
RomifidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Romifidine.
RopiniroleTrifluoperazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Trifluoperazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trifluoperazine.
RotigotineTrifluoperazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trifluoperazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Trifluoperazine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Trifluoperazine.
ScopolamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trifluoperazine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Trifluoperazine.
SertindoleThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Trifluoperazine.
SimeprevirThe metabolism of Trifluoperazine can be decreased when combined with Simeprevir.
SinefunginThe serum concentration of Trifluoperazine can be increased when it is combined with Sinefungin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Trifluoperazine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Trifluoperazine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Trifluoperazine.
SotalolTrifluoperazine may increase the hypotensive activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Trifluoperazine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Trifluoperazine.
StiripentolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Stiripentol.
SufentanilTrifluoperazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.
SulfadoxineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Trifluoperazine can be increased when it is combined with Sulfametopyrazine.
SulpirideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Trifluoperazine.
SuvorexantThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Trifluoperazine.
tafenoquineThe serum concentration of Trifluoperazine can be increased when it is combined with tafenoquine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Trifluoperazine.
TapentadolTrifluoperazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trifluoperazine.
TasimelteonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Trifluoperazine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Trifluoperazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Trifluoperazine.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Trifluoperazine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trifluoperazine.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Trifluoperazine.
TenofovirThe metabolism of Trifluoperazine can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine.
TetracaineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrodotoxin.
ThalidomideTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Trifluoperazine.
TheophyllineThe metabolism of Trifluoperazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Trifluoperazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Trifluoperazine.
TiclopidineThe metabolism of Trifluoperazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiletamine.
TimololTrifluoperazine may increase the hypotensive activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Trifluoperazine.
TopiramateThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trifluoperazine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Trifluoperazine.
TramadolTrifluoperazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Trifluoperazine.
TrazodoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triazolam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trifluoperazine.
TrimethoprimThe serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Trifluoperazine.
TriprolidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Trifluoperazine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Trifluoperazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trifluoperazine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Trifluoperazine.
VemurafenibThe serum concentration of Trifluoperazine can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Trifluoperazine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Trifluoperazine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Trifluoperazine.
VigabatrinThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Trifluoperazine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Trifluoperazine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Trifluoperazine.
VortioxetineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Trifluoperazine.
ZimelidineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Trifluoperazine.
ZolazepamThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trifluoperazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Trifluoperazine.
ZonisamideThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Lahti RA, Evans DL, Stratman NC, Figur LM: Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol. 1993 Jun 4;236(3):483-6. [PubMed:8102973 ]
  4. Schmidt MH, Lee T: Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure. Psychiatry Res. 1991 Mar;36(3):319-28. [PubMed:1676523 ]
  5. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
  6. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Clathrin light chain binding
Specific Function:
Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis.
Gene Name:
CALY
Uniprot ID:
Q9NYX4
Molecular Weight:
23433.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976 Jun 24;261(5562):717-9. [PubMed:945467 ]
  3. Madrid PB, Polgar WE, Toll L, Tanga MJ: Synthesis and antitubercular activity of phenothiazines with reduced binding to dopamine and serotonin receptors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3014-7. Epub 2007 Mar 24. [PubMed:17407813 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fujinaga M, Hoffman BB, Baden JM: Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos. Dev Biol. 1994 Apr;162(2):558-67. [PubMed:8150214 ]
  4. Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70. [PubMed:6135146 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Torres-Piedra M, Figueroa M, Hernandez-Abreu O, Ibarra-Barajas M, Navarrete-Vazquez G, Estrada-Soto S: Vasorelaxant effect of flavonoids through calmodulin inhibition: Ex vivo, in vitro, and in silico approaches. Bioorg Med Chem. 2011 Jan 1;19(1):542-6. doi: 10.1016/j.bmc.2010.10.063. Epub 2010 Nov 4. [PubMed:21129983 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Troponin t binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC1
Uniprot ID:
P63316
Molecular Weight:
18402.36 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Rage receptor binding
Specific Function:
Not Available
Gene Name:
S100A4
Uniprot ID:
P26447
Molecular Weight:
11728.41 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  2. Malashkevich VN, Dulyaninova NG, Ramagopal UA, Liriano MA, Varney KM, Knight D, Brenowitz M, Weber DJ, Almo SC, Bresnick AR: Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc Natl Acad Sci U S A. 2010 May 11;107(19):8605-10. doi: 10.1073/pnas.0913660107. Epub 2010 Apr 26. [PubMed:20421509 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
conversion inhibitor
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular Weight:
146422.99 Da
References
  1. Hirata Y, Ishii K, Taguchi T, Suita S, Takeshige K: Conversion of xanthine dehydrogenase to xanthine oxidase during ischemia of the rat small intestine and the effect of trifluoperazine on the conversion. J Pediatr Surg. 1993 Apr;28(4):597-600. [PubMed:8483075 ]
  2. Greene EL, Paller MS: Calcium and free radicals in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol. 1994 Jan;266(1 Pt 2):F13-20. [PubMed:8304479 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, Miners JO: Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos. 2009 Sep;37(9):1948-55. doi: 10.1124/dmd.109.028225. Epub 2009 Jun 1. [PubMed:19487247 ]
  2. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, Yokoi T: Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos. 2007 Oct;35(10):1781-7. Epub 2007 Jul 9. [PubMed:17620344 ]
  3. Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO: Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos. 2006 Mar;34(3):449-56. Epub 2005 Dec 28. [PubMed:16381668 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23